Open-Label, Inpatient Study of Levotofisopam 50 mg TID Administered for 7 Days to Men and Postmenopausal Women With Hyperuricemia and Gout.

Trial Profile

Open-Label, Inpatient Study of Levotofisopam 50 mg TID Administered for 7 Days to Men and Postmenopausal Women With Hyperuricemia and Gout.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Levotofisopam (Primary)
  • Indications Gout; Hyperuricaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Nov 2012 Results were presented at the American College of Rheumatology (ACR) annual meeting, according to a Pharmos Corporation media release.
    • 16 Apr 2012 Interim results published in a Pharmos Corporation Media Release.
    • 05 Apr 2012 Planned End Date changed from 1 Jun 2012 to 1 May 2012, according to a Pharmos Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top